These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1283750)

  • 41. Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports.
    Kubota K; Hasumi Y; Numata A; Tukazaki T; Horie K; Hashimoto K; Yokota H
    J Palliat Med; 2013 Jun; 16(6):596-7. PubMed ID: 23600413
    [No Abstract]   [Full Text] [Related]  

  • 42. Palliative Management of Inoperable Malignant Bowel Obstruction: Prospective, Open Label, Phase 2 Study at an NCI Comprehensive Cancer Center.
    Walter M; Hansen E; Hamid S; Carozza D; Mann G; Roche C; George A; Attwood K; Case A
    J Pain Symptom Manage; 2024 Jan; 67(1):20-26. PubMed ID: 37769820
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects of octreotide on small bowel obstructions in rats].
    Cho JH; Kang HG; Kim SH; Lee HS; Lee KR; Kang HY
    Korean J Gastroenterol; 2003 Oct; 42(4):283-8. PubMed ID: 14634347
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intestinal obstruction.
    Baines MJ
    Cancer Surv; 1994; 21():147-56. PubMed ID: 8564990
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
    J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Aggressive pharmacological treatment for reversing malignant bowel obstruction.
    Mercadante S; Ferrera P; Villari P; Marrazzo A
    J Pain Symptom Manage; 2004 Oct; 28(4):412-6. PubMed ID: 15471659
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment with octreotide for functional obstructions in scleroderma].
    Emmerich J; Roux ME; Capron L; Fiessinger JN
    Presse Med; 1992 Feb; 21(7):316-7. PubMed ID: 1532651
    [No Abstract]   [Full Text] [Related]  

  • 48. Octreotide for malignant bowel obstruction: commentary on Currow et al.
    Mercadante S
    J Pain Symptom Manage; 2015 May; 49(5):813. PubMed ID: 25863013
    [No Abstract]   [Full Text] [Related]  

  • 49. [A clinical study using octreotide in relieving gastrointestinal symptoms due to bowel obstruction in a terminally ill cancer patient].
    Shima Y; Yamaguchi K; Miyata Y; Hyodo I; Yagi Y; Honke Y
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1377-82. PubMed ID: 15446560
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases.
    Perlemuter G; Cacoub P; Chaussade S; Wechsler B; Couturier D; Piette JC
    Arthritis Rheum; 1999 Jul; 42(7):1545-9. PubMed ID: 10403284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Palliation of gastrointestinal obstruction.
    Tradounsky G
    Can Fam Physician; 2012 Jun; 58(6):648-52, e317-21. PubMed ID: 22859627
    [No Abstract]   [Full Text] [Related]  

  • 52. An unusual case of malignant gastro-intestinal obstruction in advanced cervical cancer.
    Lübbe AS; Stange JH
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):171-2. PubMed ID: 11935305
    [No Abstract]   [Full Text] [Related]  

  • 53. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
    Currow DC; Quinn S; Agar M; Fazekas B; Hardy J; McCaffrey N; Eckermann S; Abernethy AP; Clark K
    J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Application of sandostatin in malignant bowel obstruction].
    Li J; Jing ML; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2007 Sep; 10(5):479-81. PubMed ID: 17851794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gastrointestinal peptide hormones during postoperative ileus. Effect of octreotide.
    Cullen JJ; Eagon JC; Kelly KA
    Dig Dis Sci; 1994 Jun; 39(6):1179-84. PubMed ID: 7515341
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of octreotide in palliative care.
    Mercadante S
    J Pain Symptom Manage; 1994 Aug; 9(6):406-11. PubMed ID: 7525789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The palliative effects of octreotide in cancer patients.
    Dean A
    Chemotherapy; 2001; 47 Suppl 2():54-61. PubMed ID: 11275702
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of treatment-related intermittent partial small bowel obstruction: the use of octreotide.
    Myers J; Tamber A; Farhadian M
    J Pain Symptom Manage; 2010 Apr; 39(4):e1-3. PubMed ID: 20153136
    [No Abstract]   [Full Text] [Related]  

  • 59. Malignant bowel obstruction.
    Krouse RS
    J Surg Oncol; 2019 Jul; 120(1):74-77. PubMed ID: 30908650
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Improvement in survival of mice with proximal small bowel obstruction treated with octreotide.
    Gittes GK; Nelson MT; Debas HT; Mulvihill SJ
    Am J Surg; 1992 Feb; 163(2):231-3. PubMed ID: 1739178
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.